Pathfinders in Biopharma
By RBC Capital Markets
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by RBC Capital Markets
Category: Investing
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 54
Description
Perspectives from the cutting edge of biotech and pharma.
The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.
Lead today. Define tomorrow.
| Episode | Date |
|---|---|
|
MindMed: Rethinking brain health with psychedelic therapy
|
Sep 17, 2025 |
|
Funding the future of retinal health with Eyepoint
|
Sep 03, 2025 |
|
How Blackstone Life Sciences is bridging the innovation gap
|
Jul 24, 2025 |
|
Compass trials mark a milestone moment for the psychedelics sector
|
Jul 21, 2025 |
|
Cidara’s pursuit of universal flu protection with a single dose
|
Jul 11, 2025 |
|
Ocular Therapeutix’ bold vision to redefine retinal disease treatment
|
Jul 03, 2025 |
|
PTC Therapeutics: Building a durable company to benefit patients
|
Jun 27, 2025 |
|
BioAge is translating insights from the science of aging into new medicines
|
May 29, 2025 |
|
Uncertainty reigns, but opportunity persists for biotech’s 2025
|
Feb 07, 2025 |
|
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments
|
Nov 22, 2024 |
|
Former Investor Who Chose Broadcasting Over Biotech ETFs
|
Sep 30, 2024 |
|
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?
|
Aug 29, 2024 |
|
Shots-on-Goal Licensing Company Aims for Breakthroughs
|
Jul 19, 2024 |
|
Why Biopharma Needs to Tell Better Stories on Novel Drugs
|
Jul 11, 2024 |
|
Venture capital velocity: What’s driving renewed momentum in biotech?
|
Jul 08, 2024 |
|
Pharma Understands Phase One Data – But Does the Market?
|
Jun 21, 2024 |
|
Davern Capital sees GLP-1 Opportunities Beyond Obesity
|
Jun 14, 2024 |
|
Betting on Healthcare’s Future Hits – and Misses
|
Jun 10, 2024 |
|
Innovation and an Aging Population Drive MedTech
|
Jun 05, 2024 |
|
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing
|
Jun 03, 2024 |
|
Biotech with a Mission to Target Unmet Cancer Needs
|
May 31, 2024 |
|
The M&A Pool Set to Accelerate Biotech Innovation
|
Apr 03, 2024 |
|
How PIPEs finally unblocked biotech’s funding flows
|
Mar 29, 2024 |
|
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back
|
Mar 07, 2024 |
|
Will the Biotech Rebound Run into Pricing Policy Obstacles?
|
Feb 27, 2024 |
|
Few IPOs but plenty of follow-on for biotech in 2023
|
Jan 22, 2024 |
|
U.S. Outlook: Will the US economy achieve a soft landing in 2024?
|
Dec 29, 2023 |
|
Raising Venture Capital: A New Playbook for A New Era in Biotech
|
Nov 22, 2023 |
|
ECM: Robust End to Year, Despite Previous Volatility
|
Oct 31, 2023 |
|
Biotech Halftime Report: A Winding Road Ahead
|
Sep 26, 2023 |
|
The Urgent Need to Address the Youth Mental Health Landscape
|
Aug 17, 2023 |
|
Website Traffic Reveals Biopharma Sales Trends
|
Aug 07, 2023 |
|
When to Call it Quits: VCs Making Tough Decisions in a Tough Market
|
Jul 13, 2023 |
|
How Biotech M&A is Redefining the Strategic Landscape
|
Jun 23, 2023 |
|
Healthcare Should Get Ready for ‘Fast and Furious’ M&A
|
Jun 08, 2023 |
|
Innovation and Growth: Key Ingredients to Healthcare M&A
|
Jun 07, 2023 |
|
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?
|
Jun 02, 2023 |
|
Global Blood Therapeutics Commitment to Sickle-Cell Innovation
|
May 22, 2023 |
|
Is This the Breakthrough Moment for Genetic Medicine?
|
Apr 13, 2023 |
|
The Hidden Revolution Set to Turn US Healthcare on its Head
|
Jan 26, 2023 |
|
The Big Picture for Biotech
|
Dec 13, 2022 |
|
Why Biopharma Investment Requires a Different Mindset
|
Nov 22, 2022 |
|
The Optimism Behind the Biopharma Market
|
Oct 03, 2022 |
|
Biotech Investors: How to Find Value in a Bear Market
|
Mar 21, 2022 |
|
A call to action: Global Blood Therapeutics on tackling orphan disease
|
Dec 08, 2021 |
|
Ionis: Raising The Bar For ESG
|
Oct 28, 2021 |
|
Biotech and Big Pharma: Blueprint for Successful Partnership
|
Sep 30, 2021 |
|
What’s Material in ESG for Biopharma Firms?
|
May 04, 2021 |
|
Inside Track: Behind the Scenes of a Major Biotech SPAC
|
Apr 26, 2021 |
|
Biotech SPACs: A new route to going public
|
Mar 12, 2021 |
|
5AM Ventures: Fueling the Next Generation of Innovators
|
Dec 21, 2020 |
|
Vida Ventures: Powering Breakthroughs in Biopharma
|
Dec 21, 2020 |
|
Biotech IPOs: Navigating the New Landscape
|
Dec 10, 2020 |
|
Biotech IPOs: New Steps to Success on the Road to Going Public
|
Dec 02, 2020 |